Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5200735
Max Phase: Preclinical
Molecular Formula: C27H19F2N3O4S
Molecular Weight: 519.53
Associated Items:
ID: ALA5200735
Max Phase: Preclinical
Molecular Formula: C27H19F2N3O4S
Molecular Weight: 519.53
Associated Items:
Canonical SMILES: O=C1NC(=O)/C(=C\c2ccc(OCC(=O)N3N=C(c4ccccc4)CC3c3ccc(F)cc3F)cc2)S1
Standard InChI: InChI=1S/C27H19F2N3O4S/c28-18-8-11-20(21(29)13-18)23-14-22(17-4-2-1-3-5-17)31-32(23)25(33)15-36-19-9-6-16(7-10-19)12-24-26(34)30-27(35)37-24/h1-13,23H,14-15H2,(H,30,34,35)/b24-12+
Standard InChI Key: MKNSRMBCTPCUPP-WYMPLXKRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 519.53 | Molecular Weight (Monoisotopic): 519.1064 | AlogP: 5.05 | #Rotatable Bonds: 6 |
Polar Surface Area: 88.07 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 7.20 | CX Basic pKa: 0.47 | CX LogP: 4.58 | CX LogD: 4.18 |
Aromatic Rings: 3 | Heavy Atoms: 37 | QED Weighted: 0.46 | Np Likeness Score: -1.60 |
1. Upadhyay N, Tilekar K, Safuan S, Kumar AP, Schweipert M, Meyer-Almes FJ, C S R.. (2021) Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks., 12 (9.0): [PMID:34671737] [10.1039/D1MD00125F] |
Source(1):